NCT05615012

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Assess the Effect of Steady-State BMS-986322 on the Pharmacokinetics of Rosuvastatin (Part 1), the Pharmacokinetics and Pharmacodynamics of Metformin (Part 2) and the Pharmacokinetics of Methotrexate (Part 3) in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	BMS-986322	Specified dose on specified days
DRUG	Rosuvastatin	Specified dose on specified days
DRUG	Metformin	Specified dose on specified days
DIETARY_SUPPLEMENT	Glucose	Specified dose on specified days
DRUG	Methotrexate	Specified dose on specified days
DRUG	Leucovorin	Specified dose on specified days

Timeline

• Start date: 2022-11-11
• Primary completion: 2023-12-13
• Completion: 2023-12-13
• First posted: 2022-11-14
• Last updated: 2024-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study